Works matching DE "SODIUM-glucose cotransporter 2 inhibitors"
Results: 2021
Bexagliflozin in type 2 diabetes: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 7, p. 241, doi. 10.1007/s40267-024-01098-1
- By:
- Publication type:
- Article
Sex-Related Disparities in Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes and Heart Failure.
- Published in:
- Journal of Women's Health (15409996), 2023, v. 32, n. 11, p. 1219, doi. 10.1089/jwh.2023.0059
- By:
- Publication type:
- Article
SGLT2 inhibitors and diabetic retinopathy progression.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2024, v. 262, n. 3, p. 753, doi. 10.1007/s00417-023-06273-0
- By:
- Publication type:
- Article
Sodium-glucose cotransporter 2 inhibitors and contrast-induced nephropathy risk: a meta-analysis.
- Published in:
- European Journal of Clinical Pharmacology, 2025, v. 81, n. 3, p. 337, doi. 10.1007/s00228-024-03799-y
- By:
- Publication type:
- Article
Association between sodium-glucose cotransporter-2 inhibitor and adverse events in patients with moderate to severe chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
- Published in:
- European Journal of Clinical Pharmacology, 2025, v. 81, n. 2, p. 217, doi. 10.1007/s00228-024-03779-2
- By:
- Publication type:
- Article
Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.
- Published in:
- European Journal of Clinical Pharmacology, 2024, v. 80, n. 12, p. 1959, doi. 10.1007/s00228-024-03759-6
- By:
- Publication type:
- Article
Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
- Published in:
- European Journal of Clinical Pharmacology, 2024, v. 80, n. 7, p. 951, doi. 10.1007/s00228-024-03660-2
- By:
- Publication type:
- Article
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
- Published in:
- European Journal of Clinical Pharmacology, 2024, v. 80, n. 1, p. 127, doi. 10.1007/s00228-023-03586-1
- By:
- Publication type:
- Article
Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis.
- Published in:
- European Journal of Clinical Pharmacology, 2023, v. 79, n. 11, p. 1465, doi. 10.1007/s00228-023-03561-w
- By:
- Publication type:
- Article
Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022).
- Published in:
- European Journal of Clinical Pharmacology, 2023, v. 79, n. 9, p. 1239, doi. 10.1007/s00228-023-03539-8
- By:
- Publication type:
- Article
Safety of SGLT2 inhibitors in patients with different glomerular diseases treated with immunosuppressive therapies.
- Published in:
- European Journal of Clinical Pharmacology, 2023, v. 79, n. 7, p. 961, doi. 10.1007/s00228-023-03508-1
- By:
- Publication type:
- Article
Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials.
- Published in:
- European Journal of Clinical Pharmacology, 2023, v. 79, n. 6, p. 859, doi. 10.1007/s00228-023-03490-8
- By:
- Publication type:
- Article
Insights from a multicenter nationwide cohort analysis in Japan on the association of underlying conditions and pharmacological interventions with COVID-19 disease severity.
- Published in:
- Discover Public Health, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12982-024-00225-7
- By:
- Publication type:
- Article
Semaglutide May Reduce Alzheimer's Risk in Adults with T2D: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Semaglutide Linked with Reduced Risk of Alzheimer Disease in Large Observational Study.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Two Medication Classes Reduce CV, Liver Events in Persons with T2D, MASLD: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 2
- Publication type:
- Article
SGLT2i Use and Improved QoL, Functional Capacity in Adults With HF: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
SGLT2 Inhibitor Use Improves Quality of Life, Functional Capacity in Patients with Heart Failure.
- Published in:
- Patient Care (Online), 2024, p. 1
- Publication type:
- Article
SGLT2 Inhibitors Outperformed Other Oral Antidiabetic Drugs for Persons with T2D, NAFLD: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
SGLT2 Inhibitors Outperformed Other Oral Antidiabetic Drugs for Patients with T2D and NAFLD, According to New Research.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Empagliflozin-induced Myopathy.
- Published in:
- JCEM Case Reports, 2024, v. 2, n. 12, p. 1, doi. 10.1210/jcemcr/luae216
- By:
- Publication type:
- Article
Novel Approach for Treating Diabetes in a Patient With the Heterozygous Pathogenic Variant R46Q in the Insulin Gene.
- Published in:
- JCEM Case Reports, 2024, v. 2, n. 7, p. 1, doi. 10.1210/jcemcr/luae134
- By:
- Publication type:
- Article
Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors.
- Published in:
- JCEM Case Reports, 2023, v. 1, n. 1, p. 1, doi. 10.1210/jcemcr/luac018
- By:
- Publication type:
- Article
Cost-effective Analysis of Prescribed Oral Hypoglycemic Agents amongst Pre-obese and Obese Diabetic Patients in a Tertiary Care Hospital in Odisha.
- Published in:
- Global Journal of Medical Pharmaceutical & Biomedical Update, 2023, v. 18, p. 1, doi. 10.25259/GJMPBU_23_2023
- By:
- Publication type:
- Article
QSAR Studies of Sodium/Glucose Co-Transporter 2 Inhibitors as Potent Anti-Diabetic Drug Agents.
- Published in:
- Theoretical Foundations of Chemical Engineering, 2023, v. 57, p. S51, doi. 10.1134/S004057952307014X
- By:
- Publication type:
- Article
The value of natriuretic peptide testing for the diagnosis and prevention of heart failure in high-risk populations.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Effects of antidiabetic drugs on bone metabolism.
- Published in:
- Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, 2024, v. 5, n. 1, p. 85, doi. 10.1515/almed-2024-0038
- By:
- Publication type:
- Article
Baseline Sodium-Glucose Cotransporter-2 Inhibitor Use Strongly Attenuates the Uric Acid-Elevating Effect of Thiazide Exposure.
- Published in:
- European Journal of Therapeutics, 2023, v. 29, n. 4, p. 741, doi. 10.58600/eurjther1889
- By:
- Publication type:
- Article
Diagnosing and Managing Heart Failure with Preserved Ejection Fraction.
- Published in:
- Family Doctor: A Journal of the New York State Academy of Family Physicians, 2024, v. 12, n. 4, p. 39
- By:
- Publication type:
- Article
Comparative analysis of newer classes of antidiabetics and the concept of pharmaceutical care - dealing with therapeutic problems.
- Published in:
- Pharmacia (0428-0296), 2024, v. 71, n. 1, p. 1, doi. 10.3897/pharmacia.71.e120141
- By:
- Publication type:
- Article
恩格列净对2 型糖尿病合并非酒精性脂肪性肝病的影响.
- Published in:
- Progress in Modern Biomedicine, 2023, v. 23, n. 19, p. 3709, doi. 10.13241/j.cnki.pmb.2023.19.022
- By:
- Publication type:
- Article
达格列净对高血压小鼠小动脉重构的影响及机制.
- Published in:
- Progress in Modern Biomedicine, 2022, v. 22, n. 8, p. 1429, doi. 10.13241/j.cnki.pmb.2022.08.006
- By:
- Publication type:
- Article
糖-钠协同转运蛋白 2 抑制剂对心力衰竭合并糖尿病小鼠治疗效果及左心室重构影响的实验研究.
- Published in:
- Progress in Modern Biomedicine, 2021, v. 21, n. 16, p. 3032, doi. 10.13241/j.cnki.pmb.2021.16.007
- By:
- Publication type:
- Article
糖-钠协同转运蛋白2抑制剂对心力衰竭合并糖尿病小鼠治疗效果及左心室重构影响的实验研究.
- Published in:
- Progress in Modern Biomedicine, 2021, n. 13, p. 3032, doi. 10.13241/j.cnki.pmb.2021.16.007
- By:
- Publication type:
- Article
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 10, p. N.PAG, doi. 10.3390/biom12101349
- By:
- Publication type:
- Article
EDITORIAL.
- Published in:
- Medicina UPB, 2022, v. 41, n. 2, p. 99, doi. 10.18566/medupb.v41n2.a01
- By:
- Publication type:
- Article
Evidencia molecular y clínica del beneficio cardiovascular de los inhibidores SGLT2: estado del arte.
- Published in:
- Medicina UPB, 2022, v. 41, n. 2, p. 145, doi. 10.18566/medupb.v41n2.a07
- By:
- Publication type:
- Article
Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker.
- Published in:
- Clinical & Translational Medicine, 2021, v. 11, n. 6, p. 1, doi. 10.1002/ctm2.470
- By:
- Publication type:
- Article
The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study.
- Published in:
- Cardiology & Therapy, 2021, v. 10, n. 1, p. 189, doi. 10.1007/s40119-020-00208-0
- By:
- Publication type:
- Article
A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i).
- Published in:
- 2020
- By:
- Publication type:
- Letter
Individualized treatment of diabetes mellitus in older adults.
- Published in:
- Geriatrics & Gerontology International, 2024, v. 24, n. 12, p. 1257, doi. 10.1111/ggi.14979
- By:
- Publication type:
- Article
Sepsis associated with sodium glucose co-transporter 2 inhibitor in an elderly patient with chronic kidney disease.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Impact of sodium‐glucose cotransporter‐2 inhibitors on the risk of hip fracture in older patients in Japan using a nationwide administrative claims database: A matched case–control study.
- Published in:
- Geriatrics & Gerontology International, 2023, v. 23, n. 6, p. 418, doi. 10.1111/ggi.14591
- By:
- Publication type:
- Article
The agreement between measured HbA1c and optimized target HbA1c based on the Dementia Assessment Sheet for Community‐based Integrated Care System 8‐items (DASC‐8): A cross‐sectional study of elderly patients with diabetes.
- Published in:
- Geriatrics & Gerontology International, 2022, v. 22, n. 8, p. 560, doi. 10.1111/ggi.14415
- By:
- Publication type:
- Article
Not So Sweet!!: Posttransplant Diabetes - An Update for the Nephrologist.
- Published in:
- Indian Journal of Transplantation, 2023, v. 17, n. 1, p. 5, doi. 10.4103/ijot.ijot_97_22
- By:
- Publication type:
- Article
Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 501, doi. 10.1111/dom.14893
- By:
- Publication type:
- Article
Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 628, doi. 10.1111/dom.14878
- By:
- Publication type:
- Article
Ethnic and socioeconomic disparities in initiation of second‐line antidiabetic treatment for people with type 2 diabetes in England: A cross‐sectional study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 282, doi. 10.1111/dom.14874
- By:
- Publication type:
- Article
Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity‐score‐matched, new‐user design study with an active comparator using the IQVIA Medical Research Data UK database
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 156, doi. 10.1111/dom.14858
- By:
- Publication type:
- Article
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2469, doi. 10.1111/dom.14836
- By:
- Publication type:
- Article